Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Hisamitsu Pharmaceutical Inc (4530)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3,740.0 -79.0    -2.07%
02/05 - Closed. Currency in JPY ( Disclaimer )
  • Volume: 323,000
  • Bid/Ask: 3,728.0 / 3,741.0
  • Day's Range: 3,729.0 - 3,858.0
Type:  Equity
Market:  Japan
ISIN:  JP3784600003 
Hisamitsu Pharmaceutical Inc 3,740.0 -79.0 -2.07%

TYO:4530 Financials

 
This summary provides an overview of the most significant critical numbers from each of the Hisamitsu Pharmaceutical Inc financial reports, including theHisamitsu Pharmaceutical Inc income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the TYO:4530 financials over time via breakdowns of their annual reports.

For the fiscal year ended 28 February 2022, Hisamitsu Pharmaceutical Co Inc revenues increased 5% to Y120.19B. Net income applicable to common stockholders increased 4% to Y9.66B. Revenues reflect Japan segment increase of 5% to Y78.73B, Other segment increase of 13% to Y19.36B. Net income was partially offset by Freightage and packing expenses increase of 47% to Y4.13B (expense).

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

4530 Income Statement & Profits

Gross margin TTM 55.73%
Operating margin TTM 9.29%
Net Profit margin TTM 9.86%
Return on Investment TTM 3.73%
 Total Revenue  Net Income
Period Ending: Feb 29, 2024 Nov 30, 2023 Aug 31, 2023 May 31, 2023
Total Revenue 35850 34881 32096
Gross Profit 20371 19953 19929 18718
Operating Income 898 3873 4035 4362
Net Income 3693 4368 4049

4530 Balance Sheet

Quick Ratio MRQ 3.66
Current Ratio MRQ 4.22
LT Debt to Equity MRQ 0.03%
Total Debt to Equity MRQ 0.79%
 Total Assets  Total Liabilities
Period Ending: Feb 29, 2024 Nov 30, 2023 Aug 31, 2023 May 31, 2023
Total Assets 334909 320184
Total Liabilities 63414 69197 58556
Total Equity 267079 271492 275103 261628

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM 240.13
Revenue/Share TTM 1,870.88
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Feb 29, 2024 Nov 30, 2023 Aug 31, 2023 May 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4530 Price Commentary

Write your thoughts about Hisamitsu Pharmaceutical Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email